selected publications
-
Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.
British journal of haematology.
2018
Academic Article
GET IT
Times cited: 63 -
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.
Blood cancer journal.
2018
Academic Article
GET IT
Times cited: 33 -
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
Blood.
2016
Academic Article
GET IT
Times cited: 63 -
Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2016
Information Resource
GET IT
Times cited: 45 -
Central nervous system involvement in T-cell lymphoma: A single center experience.
Acta oncologica (Stockholm, Sweden).
2016
Academic Article
GET IT
Times cited: 45 -
Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2015
Academic Article
GET IT
Times cited: 41 -
High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.
Current oncology reports.
2015
Review
GET IT
Times cited: 17 -
A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
Leukemia & lymphoma.
2015
Academic Article
GET IT
Times cited: 25 -
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
The Lancet. Oncology.
2015
Academic Article
GET IT
Times cited: 152 -
Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.
The oncologist.
2014
Academic Article
GET IT
Times cited: 64 -
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
British journal of haematology.
2014
Academic Article
GET IT
Times cited: 26 -
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2014
Academic Article
GET IT
Times cited: 52 -
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Investigational new drugs.
2014
Academic Article
GET IT
Times cited: 64 -
Evolving treatment paradigms for primary mediastinal diffuse large B-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2014
Editorial Article
GET IT
Times cited: 5 -
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.
Blood.
2014
Article
GET IT
Times cited: 55 -
A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission.
Clinical lymphoma, myeloma & leukemia.
2013
Academic Article
GET IT
Times cited: 32 -
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2012
Academic Article
GET IT
Times cited: 180 -
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.
Blood.
2011
Academic Article
GET IT
Times cited: 268 -
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011
Academic Article
GET IT
Times cited: 26 -
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2010
Academic Article
GET IT
Times cited: 306 -
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.
British journal of haematology.
2010
Academic Article
GET IT
Times cited: 89 - Meta-analysis: making sense of maintenance rituximab?. Current oncology reports. 2009 Article GET IT
-
Distress in older patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2009
Academic Article
GET IT
Times cited: 118 -
A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
Clinical pharmacology and therapeutics.
2009
Academic Article
GET IT
Times cited: 35 -
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2009
Academic Article
GET IT
Times cited: 129 -
The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL).
Annals of oncology : official journal of the European Society for Medical Oncology.
2009
Academic Article
GET IT
Times cited: 157 - Do six or eight cycles work better with CHOP-14 and rituximab?. Current oncology reports. 2008 Academic Article GET IT
-
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma.
British journal of haematology.
2007
Academic Article
GET IT
Times cited: 73 -
Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy.
Annals of oncology : official journal of the European Society for Medical Oncology.
2007
Academic Article
GET IT
Times cited: 4 -
Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice.
Journal of the American Geriatrics Society.
2007
Academic Article
GET IT
Times cited: 119 -
Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.
British journal of haematology.
2006
Academic Article
GET IT
Times cited: 100 -
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.
British journal of haematology.
2005
Academic Article
GET IT
Times cited: 102 -
Primary lymphoma of the breast: a case of marginal zone B-cell lymphoma.
2004
GET IT
Times cited: 5 -
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
Blood.
2003
Academic Article
GET IT
Times cited: 191 -
Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology.
2003
Review
GET IT
Times cited: 107